Mark Mortenson Biography and Net Worth

Chief Science Officer of Clene

Mr. Mortenson is the co-inventor of the technology platform developed to produce Clene’s Clean-Surface Nanocrystal (CSN™) therapeutics, as well as the inventor/co-inventor for 30 other U.S. patents and hundreds of corresponding foreign patents.

Prior to joining Clene, Mr. Mortenson served as former Chief Operating Officer of Research, Development and Manufacturing for an advanced materials-based company of more than 300 employees. In addition to his professional experience, he is a former chief patent counsel responsible for approximately 5,500 patents and patent applications in the U.S. and 44 foreign countries. Mr. Mortenson holds both a Bachelor of Science in physics and a Bachelor of Science in ceramic engineering from Alfred University, a Master of Science in material science from Pennsylvania State University, and a Juris Doctor degree from George Washington University.

What is Mark Mortenson's net worth?: The estimated net worth of Mark Mortenson is at least $127.52 thousand as of September 30th, 2024. Mr. Mortenson owns 28,949 shares of Clene stock worth more than $127,520 as of September 23rd. This net worth estimate does not reflect any other investments that Mr. Mortenson may own. Learn More about Mark Mortenson's net worth.
How do I contact Mark Mortenson?: The corporate mailing address for Mr. Mortenson and other Clene executives is 6550 South Millrock Drive, Suite G50, Salt Lake City, UT, 84121. Clene can also be reached via phone at 801-676-9695 and via email at [email protected]. Learn More on Mark Mortenson's contact information.
Has Mark Mortenson been buying or selling shares of Clene?: Mark Mortenson has not been actively trading shares of Clene within the last three months. Most recently, on Monday, September 30th, Mark Mortenson bought 20,512 shares of Clene stock. The stock was acquired at an average cost of $4.75 per share, with a total value of $97,432.00. Following the completion of the transaction, the insider now directly owns 28,949 shares of the company's stock, valued at $137,507.75. Learn More on Mark Mortenson's trading history.
Who are Clene's active insiders?: Clene's insider roster includes David Matlin (Director), and Mark Mortenson (Chief Science Officer). Learn More on Clene's active insiders.
Are insiders buying or selling shares of Clene?: In the last twelve months, Clene insiders bought shares 1 times. They purchased a total of 33,333 shares worth more than $216,664.50. In the last twelve months, insiders at the sold shares 56 times. They sold a total of 852,916 shares worth more than $5,187,643.28. The most recent insider tranaction occured on May, 12th when Major Shareholder Chidozie Ugwumba sold 73,296 shares worth more than $454,435.20. Insiders at Clene own 28.3% of the company. Learn More about insider trades at Clene.
Information on this page was last updated on 5/12/2026.

Mark Mortenson Insider Trading History at Clene

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/30/2024	Buy	20,512	$4.75	$97,432.00	28,949

Mark Mortenson Buying and Selling Activity at Clene

Clene Company Overview

Clene Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. Its lead drug candidate is CNM-Au8, which is being studied in various clinical trials, including a completed Phase 2 platform trial to evaluate the safety and efficacy of CNM-Au8 in patients with amyotrophic lateral sclerosis (ALS); completed Phase 2 proof of concept clinical trial in patients with early symptomatic ALS; completed two open-label investigator blinded Phase 2 clinical trials on the brain's energy metabolites; completed Phase 2 clinical trial for the treatment of visual pathway deficits in chronic optic neuropathy for remyelination in stable relapsing Multiple Sclerosis; and a second Phase 2 clinical trial for the treatment of patients with Parkinson's Diseases. The company also develops CNM-AgZn17, a gel polymer suspension of silver and zinc ions that is being developed for the treatment of infectious diseases and to support wound healing; and CNM-ZnAg, a broad-spectrum antiviral and antibacterial agent to treat infection disease and to provide immune support for symptom resolution. In addition, it markets and distributes dietary supplements comprising rMetx, an aqueous zinc-silver ion dietary supplement; and KHC46, an aqueous gold dietary supplement of very low-concentration Au nanoparticles. The company is headquartered in Salt Lake City, Utah.

Today's Range

Now: $4.29

$4.15

$4.44

50 Day Range

MA: $4.61

$3.28

$6.02

2 Week Range

Now: $4.29

$3.25

$13.50

Volume

75,246 shs

Average Volume

233,151 shs

Market Capitalization

$55.73 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.95